Does NELVUTAMIG Cause Malignant neoplasm progression? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Malignant neoplasm progression have been filed in association with NELVUTAMIG. This represents 5.8% of all adverse event reports for NELVUTAMIG.
16
Reports of Malignant neoplasm progression with NELVUTAMIG
5.8%
of all NELVUTAMIG reports
3
Deaths
6
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NELVUTAMIG?
Of the 16 reports, 3 (18.8%) resulted in death, 6 (37.5%) required hospitalization, and 1 (6.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NELVUTAMIG. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does NELVUTAMIG Cause?
Off label use (29)
Immune-mediated hepatitis (18)
Hypothyroidism (17)
Immune-mediated enterocolitis (16)
Colitis (15)
Drug ineffective (14)
Immune-mediated hepatic disorder (14)
Fatigue (13)
Immune-mediated myocarditis (11)
Diarrhoea (10)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NELVUTAMIG Alternatives Have Lower Malignant neoplasm progression Risk?
NELVUTAMIG vs NEMOLIZUMAB
NELVUTAMIG vs NEMOLIZUMAB-ILTO
NELVUTAMIG vs NEOMYCIN
NELVUTAMIG vs NEORAL
NELVUTAMIG vs NEOSTIGMINE